- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00932971
HIDIT II - PegIFN-alfa2a Plus Tenofovir in Chronic Delta Hepatitis (HIDIT-II)
January 26, 2018 updated by: HepNet Study House, German Liverfoundation
A Multicenter Randomised Study Comparing the Efficacy of PegIFN-alfa2a Plus Placebo vs. PegIFN-alfa2a Plus Tenofovir for the Treatment of Chronic Delta Hepatitis-The Hep-Net International Delta Hepatitis Interventional Trial II (HIDIT-II)
Randomized, double blind study comparing the efficacy of pegylated interferon-alfa2a plus placebo versus pegylated interferon-alfa2a plus tenofovir for the treatment of chronic delta hepatitis.
70 Patients will be randomized 1:1 into the two groups.
Treatment duration: 96 weeks.
Follow-up: 24 weeks.
Long-term-follow-up: until week 358.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
70
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Berlin, Germany, 13353
- Charité Campus Virchow-Klinikum, Med. Klinik für Gastroenterologie und Hepatologie
-
Bonn, Germany, 53105
- Friedrich-Wilhelms-Universität, Med. Klinik und Poliklinik I
-
Düsseldorf, Germany, 40225
- Universitätsklinikum Düsseldorf, Klinik für Gastroenterologie
-
Frankfurt, Germany, 60590
- Klinikum der J.W. Goethe-Universitat
-
Hamburg, Germany, 20246
- Universitätsklinikum Hamburg-Eppendorf, Klinik für Innere Medizin
-
Hannover, Germany, 30625
- Medizinische Hochschule Hannover, Zentrum Innere Medizin
-
Heidelberg, Germany, 69120
- Medizinische Fakultät der Universität Heidelberg, Innere Medizin IV
-
-
-
-
-
Athens, Greece, 11527
- Athens University School of Medicine, Hippokration General Hospital
-
-
-
-
-
Bucharest, Romania, 021105
- Institutul de Boli Infectioase "Prof. Dr. Matei Bals"
-
Timisoara, Romania, 300312
- Spitalul Clinic de Boli Infectioase si
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Written informed consent.
- Age > 18 years.
- Positive HBsAg, for at least the prior 6 months, positive anti-HDV for at least 3 months and positive for HDV-RNA by PCR within the screening period.
- Elevated serum ALT ≥ ULN but ≤ 10X ULN as determined by two abnormal values taken > 1 month apart during the 12 months before the first dose of study drug with at least one of the determinations obtained ≤ 35 days prior to the first dose.
- A liver biopsy obtained within the past 12 months demonstrating liver disease consistent with chronic hepatitis. Patients with cirrhosis on liver biopsy must also have a liver imaging investigation to rule out hepatic carcinoma.
- Negative urine or serum pregnancy test documented within the 24 hour period prior to the first dose of test drug.
- Additionally, all fertile males with partners of childbearing age and females should use two reliable forms of effective contraception (combined) throughout the entire period of the study (treatment and for 4 months after treatment completion)
- Creatinine clearance ≥ 70 mL/min
Exclusion Criteria:
- Patients must not have received antiviral therapy for their chronic hepatitis D within the previous 6 months. Patients who are expected to need systemic antiviral therapy other than that provided by the study at any time during their participation in the study are also excluded.
- Positive test at screening for HAV-Ag-IgM, HCV-RNA or HCV-Ag or HIV-Ag.
- Serum concentrations of ceruloplasmin or alpha-1-antitrypsin consistent with an increased risk of metabolic liver disease.
- Evidence of decompensated liver disease (Childs B-C).
- History or other evidence of a medical condition associated with chronic liver disease (e.g., hemochromatosis, autoimmune hepatitis, alcoholic liver disease, toxin exposures, thalassemia).
- Women with ongoing pregnancy or who are breast feeding.
- WBC count of < 3.000 cells/ mm3; neutrophil count < 1.500 cells/mm3or platelet count < 90.000 cells/mm3.
- Evidence of alcohol and/or drug abuse within one year of entry.
- Patients are excluded if any history of psychiatric disease, especially depression, or of suicidal attempts is evident.
- History of immunologically mediated disease.
- History or other evidence of decompensated liver disease.
- History or other evidence of chronic pulmonary disease associated with functional limitation.
- History of severe cardiac disease
- Evidence of an active or suspected cancer or a history of malignancy where there is a risk of cancer to recur.
- History of having received any systemic anti-neoplastic (including radiation) or immunomodulatory treatment (including systemic corticosteroids) ≤ 6 months prior to the first dose of study drug or the expectation that such treatment will be needed at any time during the study.
- History of any organ transplantation with an existing functional graft
- History of thyroid disease poorly controlled on prescribed medications. Patients with elevated thyroid stimulating hormone concentrations with elevation of antibodies to thyroid peroxidase and any clinical manifestations of thyroid disease are excluded.
- History or evidence of severe retinopathy or clinically relevant ophthalmological disorder.
- Inability or unwillingness to provide informed consent or abide by the requirements of the study.
- History or other evidence of severe illness or any other conditions which would make the patient, in the opinion of the investigator, unsuitable for the study.
- Patients with a value of alpha-fetoprotein >100 ng/mL are excluded, unless stability (less than 10% increase) has been documented over at least the previous 3 months.
- History or evidence for any intolerance or hypersensitivity to pegylated interferon-alfa-2a, tenofovir or other substances part of the study medication.
- Current participation in any other investigational trial and participation in another investigational trial within 3 months before the trial begins.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: PEG-IFN alfa-2a plus placebo
Pegylated interferon alfa-2a 180 µg once weekly (QW) subcutaneous (sc) plus placebo once daily, orally
|
Pegylated interferon alfa-2a, 180µg once weekly, subcutaneously; Placebo, once daily, orally
Other Names:
|
Active Comparator: PEG-IFN alfa-2a plus Tenofovir
Pegylated interferon alfa-2a 180 µg once weekly (QW) subcutaneous (sc) plus Tenofovir disoproxilfumarat 245mg once daily, orally
|
Pegylated interferon alfa-2a, 180µg once weekly, subcutaneously; Tenofovir disoproxilfumarat, 245mg, once daily, orally
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Negativation of HDV-RNA at the end of therapy
Time Frame: week 96
|
week 96
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Negativation of HDV-RNA at week 48 of treatment
Time Frame: week 48
|
week 48
|
Negativation of HDV-RNA 24 weeks after the end of treatment
Time Frame: week 120
|
week 120
|
Normalization of ALT levels at the end of treatment and at the end of follow-up
Time Frame: week 96 and week 356
|
week 96 and week 356
|
HDV-RNA-levels over time
Time Frame: up to week 356
|
up to week 356
|
Suppression of HBV-DNA below 6 IU/ml using the Cobas TaqMan assay at treatment weeks 48 and 96 and 24 weeks after treatment
Time Frame: week 48, week 96, week 120
|
week 48, week 96, week 120
|
Liver histology at end of treatment (Ishak score for inflammation and fibrosis)
Time Frame: week 96
|
week 96
|
Quantitative HBsAg levels over time. Loss of HBsAg and development of anti-HBs antibodies, intrahepatic cccDNA and HBV-DNA levels over time
Time Frame: up to week 356
|
up to week 356
|
HBV- and HDV-virus-specific T cell responses during therapy and after 24 weeks of follow up if virological and biochemical efficacy has been shown
Time Frame: up week 120
|
up week 120
|
Virological long-term outcome
Time Frame: 1, 2, 3, 4 and 5 years after the end of treatment
|
1, 2, 3, 4 and 5 years after the end of treatment
|
Clinical long-term outcome
Time Frame: 1, 2, 3, 4 and 5 years after the end of treatment
|
1, 2, 3, 4 and 5 years after the end of treatment
|
Quality of Life
Time Frame: up to week 356
|
up to week 356
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Study Director: Michael P. Manns, Prof. Dr., Hannover Medical School
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Heidrich B, Deterding K, Tillmann HL, Raupach R, Manns MP, Wedemeyer H. Virological and clinical characteristics of delta hepatitis in Central Europe. J Viral Hepat. 2009 Dec;16(12):883-94. doi: 10.1111/j.1365-2893.2009.01144.x. Epub 2009 Jun 28.
- Wedemeyer H, Yurdaydin C, Dalekos GN, Erhardt A, Cakaloglu Y, Degertekin H, Gurel S, Zeuzem S, Zachou K, Bozkaya H, Koch A, Bock T, Dienes HP, Manns MP; HIDIT Study Group. Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med. 2011 Jan 27;364(4):322-31. doi: 10.1056/NEJMoa0912696.
- Heidrich B, Yurdaydin C, Kabacam G, Ratsch BA, Zachou K, Bremer B, Dalekos GN, Erhardt A, Tabak F, Yalcin K, Gurel S, Zeuzem S, Cornberg M, Bock CT, Manns MP, Wedemeyer H; HIDIT-1 Study Group. Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta. Hepatology. 2014 Jul;60(1):87-97. doi: 10.1002/hep.27102.
- Wedemeyer H, Yurdaydin C, Hardtke S, Caruntu FA, Curescu MG, Yalcin K, Akarca US, Gurel S, Zeuzem S, Erhardt A, Luth S, Papatheodoridis GV, Keskin O, Port K, Radu M, Celen MK, Idilman R, Weber K, Stift J, Wittkop U, Heidrich B, Mederacke I, von der Leyen H, Dienes HP, Cornberg M, Koch A, Manns MP; HIDIT-II study team. Peginterferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial. Lancet Infect Dis. 2019 Mar;19(3):275-286. doi: 10.1016/S1473-3099(18)30663-7.
- Bremer B, Anastasiou OE, Ciesek S, Wedemeyer H. Automated nucleic acid isolation methods for HDV viral load quantification can lead to viral load underestimation. Antivir Ther. 2019;24(2):117-123. doi: 10.3851/IMP3281.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2009
Primary Completion (Actual)
August 1, 2017
Study Completion (Actual)
August 2, 2017
Study Registration Dates
First Submitted
July 3, 2009
First Submitted That Met QC Criteria
July 6, 2009
First Posted (Estimate)
July 7, 2009
Study Record Updates
Last Update Posted (Actual)
January 29, 2018
Last Update Submitted That Met QC Criteria
January 26, 2018
Last Verified
January 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- RNA Virus Infections
- Virus Diseases
- Infections
- Liver Diseases
- Hepatitis, Viral, Human
- Enterovirus Infections
- Picornaviridae Infections
- Hepatitis, Chronic
- Hepatitis
- Hepatitis A
- Hepatitis D
- Hepatitis D, Chronic
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Reverse Transcriptase Inhibitors
- Nucleic Acid Synthesis Inhibitors
- Enzyme Inhibitors
- Anti-HIV Agents
- Anti-Retroviral Agents
- Antineoplastic Agents
- Immunologic Factors
- Tenofovir
- Interferon-alpha
- Peginterferon alfa-2a
- Interferon alpha-2
- Interferon-alfa-1b
Other Study ID Numbers
- Hep-Net-HIDIT-II
- EudraCT-No.: 2008-005560-13
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hepatitis D
-
Eiger BioPharmaceuticalsCompleted
-
Eiger BioPharmaceuticalsAnkara UniversityCompletedChronic Hepatitis D InfectionTurkey
-
Gilead SciencesRecruitingChronic Hepatitis D InfectionUnited States
-
Hepatera Ltd.CompletedChronic Hepatitis D Infection
-
Ziauddin HospitalUnknown
-
Gilead SciencesRecruitingChronic Hepatitis D InfectionAustria, France, Germany, Spain, Romania
-
Shanghai HEP Pharmaceutical Co., Ltd.CompletedChronic Hepatitis D InfectionChina, Mongolia
-
Asian Pacific Liver Center at Coalition of Inclusive...Gilead SciencesNot yet recruitingChronic Hepatitis D Infection With Hepatitis BUnited States
-
Hepatera Ltd.Data Matrix SolutionsCompletedChronic Hepatitis D Infection With Hepatitis BRussian Federation, Germany
-
Karolinska University HospitalRecruiting
Clinical Trials on PEG-IFN alfa-2a, placebo
-
Beijing Ditan HospitalUnknownChronic Hepatitis B InfectionChina
-
Yao XieUnknownChronic Hepatitis B InfectionChina
-
Beijing Ditan HospitalUnknownChronic Hepatitis B InfectionChina
-
Beijing Ditan HospitalUnknownChronic Hepatitis B InfectionChina
-
Beijing Ditan HospitalUnknown
-
Hoffmann-La RocheCompletedHealthy VolunteersNew Zealand, Taiwan, Australia, Hong Kong, Singapore
-
Beijing Ditan HospitalUnknown
-
Gilead SciencesCompletedChronic Hepatitis DeltaFrance, Moldova, Republic of, Romania, Russian Federation
-
Hoffmann-La RocheCompletedHepatitis B, ChronicThailand, China, Italy, United Kingdom, Korea, Republic of, Taiwan, Austria, Bulgaria, Germany, New Zealand, France, Poland, Portugal, Romania, Greece
-
Hoffmann-La RocheCompletedHepatitis C, ChronicBelgium, United States, Germany, Canada, Austria, Switzerland, Puerto Rico, Australia, Brazil, Mexico